Menu
Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ
History
Thyroxine antagonism o
Principal Investigator
Principal Investigator
Biomarkers of acetamin
The Use of Modified Su
See All (36) pages
Keywords
Last Name
Institution
@uada.edu
@ualr.edu
@uapb.edu
@uark.edu
University of Arkansas for Medical Sciences
More Search Options
Announcement
You can now add alternative names!
Click here
to add other names that you've published under.
The Use of Modified Surrogate End Points in Cancer Clinical Trials.
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
View in:
PubMed
subject areas
Clinical Trials as Topic
Humans
Neoplasms
United States
United States Food and Drug Administration
authors with profiles
Samer Al Hadidi
The Use of Modified Surrogate End Points in Cancer Clinical Trials.